Factor H for treatment of rheumatoid arthritis
View Patent ↗The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H.
1. A method for treating rheumatoid arthritis in a subject in need thereof, said method comprising administering a composition comprising Factor H (FH) to said subject, wherein said FH comprises SEQ ID NO: 1.
2. The method of claim 1 , wherein said FH is a recombinant FH.
3. The method of claim 1 , wherein said FH is a protective variant.
4. The method of claim 1 , wherein said FH is administered to said subject intravenously.
5. The method of claim 1 , wherein said FH is administered to said subject by intra-articular injection.
6. The method of claim 5 , wherein said injection is to a joint of a member selected from the group consisting of: hand, foot, cervical spine, shoulder and knee.
7. The method of claim 1 , wherein the method comprises reducing joint inflammation in said subject.
8. The method of claim 1 , wherein the method comprises inhibiting an initial inflammatory response in said subject.
9. The method of claim 1 , wherein the method comprises promoting resolution of an inflammatory response in said subject.
10. The method of claim 1 , wherein the method comprises reducing exostosis in said subject.
11. The method of claim 1 , wherein the method comprises reducing damage to cartilage in said subject as compared to a subject that has not received FH.
12. The method of claim 1 , wherein said composition further comprises a plasma-derived FH.
13. The method of claim 1 , wherein said FH is administered in an amount effective to reduce damage to cartilage in the subject as compared to a subject that has not received said FH.
14. The method of claim 1 , wherein said FH is administered in a therapeutically effective dose between 0.05 mg/mL and 10 mg/mL.
15. The method of claim 1 , wherein said FH is administered in a therapeutically effective dose between 0.1 mg/mL and 10 mg/mL.
16. The method of claim 1 , wherein said FH composition for administration comprises an FH protein concentration of between 10 g/L and 250 g/L.
17. The method of claim 1 , wherein said FH is administered in a therapeutically effective dose that results in a plasma level concentration in the subject of 0.05 mg/mL and 10 mg/mL.
18. The method of claim 1 , wherein said FH is administered in a therapeutically effective dose that results in a plasma level concentration in the subject of between 0.1 mg/mL and 10 mg/mL.
19. The method of claim 1 , wherein said FH is administered in a therapeutically effective dose that results in a plasma level concentration in the subject of between 0.1 mg/mL and 5 mg/mL.
20. The method of claim 1 , wherein said FH is administered in a therapeutically effective dose that results in a plasma level concentration in the subject of between 1 mg/mL and 2 mg/mL.
21. The method of claim 1 , wherein said FH is administered to the subject in a therapeutically effective dose of 50 mg/kg to 150 mg/kg.